In summary, patients with progressive disease after first-line VEGFR TKIs will go on to receive a checkpoint inhibitor making cabozantinib a third-line agent for the vast majority of RCC patients not eligible for clinical trials. The gene discussed is KDR; the disease is renal cell adenocarcinoma.